The observed neuroprotective effects of combination therapy are likely attributed to reduced delayed tPA-induced ICH, reduced neuroinflammation, attenuated thrombosis formation in downstream microvessels, and reduced post-stroke platelet activation and platelet-leukocyte aggregation. This evidence concerns the gene PLAT and stroke disorder.